Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InflaRx (IFRX) Consolidated Net Income (2022 - 2025)

Historic Consolidated Net Income for InflaRx (IFRX) over the last 4 years, with Q3 2025 value amounting to -$10.6 million.

  • InflaRx's Consolidated Net Income rose 3414.13% to -$10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.4 million, marking a year-over-year increase of 1734.05%. This contributed to the annual value of -$49.9 million for FY2024, which is 860.33% down from last year.
  • InflaRx's Consolidated Net Income amounted to -$10.6 million in Q3 2025, which was up 3414.13% from -$14.0 million recorded in Q2 2025.
  • In the past 5 years, InflaRx's Consolidated Net Income ranged from a high of $495.4 billion in Q1 2023 and a low of -$16.6 million during Q1 2022
  • Over the past 4 years, InflaRx's median Consolidated Net Income value was -$10.8 million (recorded in 2023), while the average stood at $46.9 billion.
  • Over the last 5 years, InflaRx's Consolidated Net Income had its largest YoY gain of 298146301.83% in 2023, and its largest YoY loss of 79767.91% in 2023.
  • Over the past 4 years, InflaRx's Consolidated Net Income (Quarter) stood at -$7.5 million in 2022, then crashed by 74.2% to -$13.1 million in 2023, then increased by 26.13% to -$9.7 million in 2024, then fell by 8.68% to -$10.6 million in 2025.
  • Its Consolidated Net Income stands at -$10.6 million for Q3 2025, versus -$14.0 million for Q2 2025 and -$13.2 million for Q1 2025.